Next Article in Journal
A Comparison between Hi-C and 10X Genomics Linked Read Sequencing for Whole Genome Phasing in Hanwoo Cattle
Next Article in Special Issue
Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs
Previous Article in Journal
The Spectrum of Mutations of Homocystinuria in the MENA Region
Previous Article in Special Issue
The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 11
Issue 3
10.3390/genes11030331
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities

by
Jamie L. Grit
1,
Matt G. Pridgeon
1,2,
Curt J. Essenburg
1,
Emily Wolfrum
3,
Zachary B. Madaj
3,
Lisa Turner
4,
Julia Wulfkuhle
5,
Emanuel F. Petricoin III
5,
Carrie R. Graveel
1,† and
Matthew R. Steensma
1,2,6,*,†
1
Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI 49503, USA
2
Helen DeVos Children’s Hospital, Spectrum Health System, Grand Rapids, MI 49503, USA
3
Bioinformatics & Biostatistics Core, Van Andel Research Institute, Grand Rapids, MI 49503, USA
4
Pathology and Biorepository Core, Van Andel Research Institute, Grand Rapids, MI 49503, USA
5
Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 22030, USA
6
Michigan State University College of Human Medicine, Grand Rapids, MI 49503, USA
*
Author to whom correspondence should be addressed.
†
These authors contributed equally.
Genes 2020, 11(3), 331; https://doi.org/10.3390/genes11030331
Submission received: 1 February 2020 / Revised: 27 February 2020 / Accepted: 9 March 2020 / Published: 20 March 2020
(This article belongs to the Special Issue Genomics and Models of Nerve Sheath Tumors)
Browse Figures
Versions Notes

Abstract

Neurofibromatosis Type 1 (NF1)-related Malignant Peripheral Nerve Sheath Tumors (MPNST) are highly resistant sarcomas that account for significant mortality. The mechanisms of therapy resistance are not well-understood in MPNSTs, particularly with respect to kinase inhibition strategies. In this study, we aimed to quantify the impact of both the genomic context and targeted therapy on MPNST resistance using reverse phase phosphoproteome array (RPPA) analysis. We treated tumorgrafts from three genetically engineered mouse models using MET (capmatinib) and MEK (trametinib) inhibitors and doxorubicin, and assessed phosphosignaling at 4 h, 2 days, and 21 days. Baseline kinase signaling in our mouse models recapitulated an MET-addicted state (NF1-MET), P53 mutation (NF1-P53), and HGF overexpression (NF1). Following perturbation with the drug, we observed broad and redundant kinome adaptations that extended well beyond canonical RAS/ERK or PI3K/AKT/mTOR signaling. MET and MEK inhibition were both associated with an initial inflammatory response mediated by kinases in the JAK/STAT pathway and NFkB. Growth signaling predominated at the 2-day and 21-day time points as a result of broad RTK and intracellular kinase activation. Interestingly, AXL and NFkB were strongly activated at the 2-day and 21-day time points, and tightly correlated, regardless of the treatment type or genomic context. The degree of kinome adaptation observed in innately resistant tumors was significantly less than the surviving fractions of responsive tumors that exhibited a latency period before reinitiating growth. Lastly, doxorubicin resistance was associated with kinome adaptations that strongly favored growth and survival signaling. These observations confirm that MPNSTs are capable of profound signaling plasticity in the face of kinase inhibition or DNA damaging agent administration. It is possible that by targeting AXL or NFkB, therapy resistance can be mitigated.
Keywords: MPNST; NF1; kinase; kinome adaptation; kinome reprogramming; MET; MEK; doxorubicin; capmatinib; tram MPNST; NF1; kinase; kinome adaptation; kinome reprogramming; MET; MEK; doxorubicin; capmatinib; tram

Share and Cite

MDPI and ACS Style

Grit, J.L.; Pridgeon, M.G.; Essenburg, C.J.; Wolfrum, E.; Madaj, Z.B.; Turner, L.; Wulfkuhle, J.; Petricoin, E.F., III; Graveel, C.R.; Steensma, M.R. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities. Genes 2020, 11, 331. https://doi.org/10.3390/genes11030331

AMA Style

Grit JL, Pridgeon MG, Essenburg CJ, Wolfrum E, Madaj ZB, Turner L, Wulfkuhle J, Petricoin EF III, Graveel CR, Steensma MR. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities. Genes. 2020; 11(3):331. https://doi.org/10.3390/genes11030331

Chicago/Turabian Style

Grit, Jamie L., Matt G. Pridgeon, Curt J. Essenburg, Emily Wolfrum, Zachary B. Madaj, Lisa Turner, Julia Wulfkuhle, Emanuel F. Petricoin, III, Carrie R. Graveel, and Matthew R. Steensma. 2020. "Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities" Genes 11, no. 3: 331. https://doi.org/10.3390/genes11030331

APA Style

Grit, J. L., Pridgeon, M. G., Essenburg, C. J., Wolfrum, E., Madaj, Z. B., Turner, L., Wulfkuhle, J., Petricoin, E. F., III, Graveel, C. R., & Steensma, M. R. (2020). Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities. Genes, 11(3), 331. https://doi.org/10.3390/genes11030331

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop